Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth

Microbes and Infection

Volumn 3, Issue 1, 2001, Pages 23-35

  Høiby, Niels ^a   Krogh Johansen, Helle ^a   Moser, Claus ^a   Song, Zhijun ^a   Ciofu, Oana ^a   Kharazmi, Arsalan ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Alginate; Biofilm; Cystic fibrosis; Inflammation; Pseudomonas aeruginosa

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CORTISONE; CYTOKINE; GAMMA INTERFERON; OXYGEN RADICAL; PIPERACILLIN; PROTEINASE; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIGEN ANTIBODY COMPLEX; BACTERIAL GROWTH; BIOFILM; CHRONIC INFLAMMATION; CLINICAL FEATURE; CYSTIC FIBROSIS; GINSENG; HUMAN; IMMUNE RESPONSE; LUNG INFECTION; LUNG PARENCHYMA; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; TISSUE INJURY;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG RESISTANCE, MICROBIAL; ENDOPEPTIDASES; HUMANS; INFLAMMATION; LUNG; NEUTROPHILS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

PSEUDOMONAS; PSEUDOMONAS AERUGINOSA;

EID: 0035113461     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(00)01349-6     Document Type: Review

References (138)

1. Biofilms, the customized microniche
2. Robbins device in biofilm research
3. In situ gene expression in mixed-culture biofilms. Evidence of metabolic interactions between community members
4. Animal models of chronic pneumonia (rodents)
5. Chronic Pseudomonas aeruginosa lung infection is more severe in Th-2 responding BALB/c mice compared to Th-1 responding C3H/HeN mice
6. The immune response to bacterial biofilms
7. Morphological evidence for penetration of anti-O antibody through the capsule of Klebsiella pneumoniae
8. IgG antibodies can penetrate P. aeruginosa biofilms and inhibit beta-lactamase activity
9. Transport of 1μm latex particles in Pseudomonas aeruginosa biofilm
10. Optical sectioning of microbial biofilms
11. Influence of growth rate on susceptibility to antimicrobial agents - Modification of the cell envelope and batch and continuous culture studies
12. The involvement of cell-to-cell signals in the development of a bacterial biofilm
13. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen
14. Biofilms: An overview of bacterial adhesion, activity, and control at surfaces
15. Surface hydrophobicity and dispersal of Pseudomonas aeruginosa from biofilms
16. Polyacrylamide gel electrophoresis analysis of lipopolysaccharide from Pseudomonas aeruginosa growing planktonically and as biofilm
17. Polyagglutinable Pseudomonas aeruginosa from cystic fibrosis patients - A survey
18. The occurrence of a common lipopolysaccharide antigen in standard and clinical strains of Pseudomonas aeruginosa
19. Bacteriophages in sputum of cystic fibrosis patients as a possible cause of in vivo changes in serotypes of Pseudomonas aeruginosa
20. In vitro and in vivo changes of serotype in Pseudomonas aeruginosa isolates by anti-pseudomonal drugs
21. Theoretical aspects of antibiotic diffusion into microbial biofilms
22. Inhibition of Tobramycin diffusion by binding to alginate
23. Establishment of aging biofilms possible mechanism of bacterial resistance to antimicrobial therapy
24. Effect of polyurethane catheters and bacterial biofilms on the in-vitro activity of antimicrobials against Staphylococcus epidermidis
25. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone
26. Testing the susceptibility of bacteria in biofilms to antibacterial agents
27. Testing antimicrobial susceptibilities of adherent bacteria by a method that incorporates guidelines of the National Committee for Clinical Laboratory Standards
28. The efficacy of antibiotics enhanced by electrical currents against Pseudomonas aeruginosa biofilms
29. Electric fields (biofilm killing)
30. The effect of ultrasonic frequency upon enhanced killing of P. aeruginosa biofilms
31. Photomechanical drug delivery into bacterial biofilms
32. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
33. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis
34. Pathogenesis of cystic fibrosis
35. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis
36. Ecology and Epidemiology of Pseudomonas aeruginosa
37. Genotyping of Pseudomonas aeruginosa sputum and stool isolates from cystic fibrosis patients - Evidence for intestinal colonization and spreading into toilets
38. Pseudomonas aeruginosa colonization of the gastrointestinal tract in patients with cystic fibrosis
39. Fecal isolation of Pseudomonas aeruginosa from patients with cystic fibrosis
40. Interactions of Pseudomonas aeruginosa proteases with the cells of the immune system
41. Detection of proteases of Pseudomonas aeruginosa in immune complexes isolated from sputum of cystic fibrosis patients
42. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis
43. Microbial pathogenesis in cystic fibrosis mucoid Pseudomonas aeruginosa and Burkholderia cepacia
44. Pulmonary dehydration and infection in cystic fibrosis. Evidence that ethanol activates gene expression and induction of mucoidy in Pseudomonas aeruginosa
45. Host inflammatory responses to first isolation of Pseudomonas aeruginosa from sputum in cystic fibrosis
46. Hydrogen peroxide and nitric oxide in exhaled air of children with cystic fibrosis during antibiotic treatment
47. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide, a mechanism for virulence activation in the cystic fibrosis lung
48. Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response
49. Prevalence of mucoid strains of Pseudomonas aeruginosa in bacteriological specimens from patients with cystic fibrosis and patients with other diseases
50. Antibodies against Pseudomonas aeruginosa in sera from normal persons and from patients colonized with mucoid or non-mucoid Pseudomonas aeruginosa: Results obtained by means of crossed immunoelectrophoresis
51. Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response
52. Induction of beta-lactamase production in Pseudomonas aeruginosa biofilm
53. Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilm
54. Susceptibility of biofilm cells of Pseudomonas aeruginosa to bactericidal actions of whole blood and serum
55. Avidity of anti-P. aeruginosa antibodies during chronic infection in patients with cystic fibrosis
56. Complement deposition by antibodies to Pseudomonas aeruginosa mucoid exopolysaccharide (MEP) and by non-MEP specific opsonins
57. Prevalence and persistance of polyagglutinable Pseudomonas aeruginosa in cystic fibrosis patients
58. Polyagglutinability due to loss of 0-antigenic determinants in Pseudomonas aeruginosa strains isolated from cystic fibrosis patients
59. Serum antibodies to Pseudomonas aeruginosa outer-membrane proteins and iron-regulated membrane proteins at different stages of chronic cystic fibrosis lung infection
60. Lipopolysaccharide is present in immune complexes isolated from sputum in patients with cystic fibrosis and chronic Pseudomonas aeruginosa lung infection
61. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs
62. Current understanding of the inflammatory process in cystic fibrosis onset and etiology
63. Immunoglobulins and albumin in sputum from patients with cystic fibrosis. A study of protein stability and presence of proteases
64. The role of immune complexes in the pathogenesis of bacterial infections
65. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis
66. Excretion of urinary collagen metabolites correlates to severity of pulmonary disease in cystic fibrosis
67. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation (vol 150, p. 448, 1994)
68. Interferon-gamma (IFN-gamma) treatment decreases the inflammatory response in chronic Pseudomonas aeruginosa pneumonia in rats
69. Potential of preventing Pseudomonas aeruginosa lung infections in cystic fibrosis patients: Experimental studies in animals
70. The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type
71. Diverse Pseudomonas aeruginosa gene products stimulate respiratory epithelial cells to produce interleukin-8
72. The Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-1-homoserine lactone has immunomodulatory activity
73. Bacterial quorum sensing in pathogenic relationships
74. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment
75. The changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients, 1974-1995
76. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
77. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients
78. Improved survival in the Danish cystic fibrosis centre results of aggressive treatment
79. Regular 3 monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa
80. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
81. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
82. Dynamic interactions of biofilms of mucoid Pseudomonas aeruginosa with tobramycin and piperacillin
83. Pseudomonas aeruginosa biofilms are more susceptible to ciprofloxacin than to tobramycin
84. Effect of subinhibitory concentrations of ciprofloxacin and gentamicin on the adherence of Pseudomonas aeruginosa to Vero cells and voided uroepithelial cells
85. Alterations in Pseudomonas aeruginosa exoproducts by sub-MICs of some antibiotics
86. Inhibition of Pseudomonas aeruginosa exoenzyme expression by subinhibitory antibiotic concentrations
87. Subinhibitory antibiotics reduce Pseudomonas aeruginosa tissue injury in the rat lung model
88. Subinhibitory concentrations of tetracycline inhibit surface expression of the Pseudomonas aeruginosa ferripyochelin binding protein in vivo
89. Erythromycin inhibits the production of elastase by Pseudomonas aeruginosa without affecting its proliferation in vitro
90. Therapeutic possibilities for diffuse panbronchiolitis
91. Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin
92. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics
93. Airway biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides
94. Inhibitory activity of clarithromycin on biofilm synthesis with Pseudomonas aeruginosa
95. Combined imipenem/cilistatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis
96. Inflammatory markers in cystic fibrosis
97. Modification of some markers of inflammation during treatment for acute respiratory exacerbations in cystic fibrosis
98. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis
99. A review of the recent progress in treatment of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan
100. Long-term azithromycin may improve lung function in children with cystic fibrosis
101. Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection
102. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF center
103. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection
104. Changes in serotype caused by cell to cell contact between different Pseudomonas aeruginosa strains from cystic fibrosis patients
105. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in vivo selection of stable partially derepressed beta-lactamase producing strains
106. High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment
107. High level beta-lactamase activity in sputum from cystic fibrosis patients during anti-pseudomonal treatment
108. Chromosomal beta-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa
109. Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams
110. The influence of allotypes on the IgG subclass response to chromosomal beta-lactamase of Pseudomonas aeruginosa in cystic fibrosis patients
111. Quantitative analysis of the IgG and IgG subclass immune response to chromosomal Pseudomonas aeruginosa beta-lactamase in sera from cystic fibrosis patients by means of Western-blotting and laser scanning densitometry
112. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients
113. Comparison of the efficacy and safety of ciprofloxacin and ofloxacin in the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients
114. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection
115. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre
116. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis
117. Effect of high-dose ibuprofen in patients with cystic fibrosis
118. A preliminary study on the effect of anti-inflammatory treatment in cystic fibrosis patients with Pseudomonas aeruginosa lung infection
119. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection
120. Allotypes of alpha-1-antitrypsin in patients with cystic fibrosis, homozygous for deltaF508
121. Aerosol alpha1-antitrypsin treatment for cystic fibrosis
122. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis
123. Ginseng treatment reduces bacterial load and lung pathology in chronic Pseudomonas aeruginosa pneumonia in rats
124. Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa
125. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients
126. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark
127. Role of alginate in the adherence of Pseudomonas aeruginosa
128. Pseudomonas aeruginosa exoenzyme-S is an adhesin
129. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection
130. Mechanisms involved in the evasion of the host defence by Pseudomonas aeruginosa
131. Pseudomonas aeruginosa infection in cystic fibrosis and its management
132. Neutrophil elastase cleaves C3Bi on opsonized Pseudomonas as well as Cr1 on neutrophils to create a functionally important opsonin receptor mismatch
133. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis
134. The imbalance between granulocyte neutral proteases and antiproteases in bronchial secretions from patients with cystic fibrosis
135. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor
136. Some bacterial parameters influencing the neutrophil oxidative burst response to Pseudomonas aeruginosa biofilms